Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 11;12:3579. doi: 10.1038/s41467-021-23681-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 7 — A The protein level of OVOL2 in HOSEpiC and NOY1 cells by western blot. B The relative mRNA expression levels of OVOL2 in control and siRNA-knockdown cells. N = 3 independent experiments. Two-tailed Student’s t-test, siRNA-NC vs. siRNA-1: p < 10⁻⁴, siRNA-NC vs. siRNA-2: p < 10⁻⁴. C Drug response across different drug concentrations. NOY1 cells were transfected with siRNAs for 48 h and further treated with gradient concentration of cisplatin (0, 20, 40, 80 µM) for additional 48 h. Cell viability was detected by CellTiter-Glo assay and the relative viability was normalized to the respective noncisplatin-treated conditions. N = 3 independent experiments. Two-tailed Student’s t-test, at 40 µM cisplatin treatment condition, siRNA-NC vs. siRNA-1: p = 3.5 × 10⁻², siRNA-NC vs. siRNA-2: p = 2.3 × 10⁻³; at 80 µM cisplatin condition, siRNA-NC vs. siRNA-1: p = 7.2 × 10⁻³, siRNA-NC vs. siRNA-2: p = 4.0 × 10⁻⁴. D Drug response across different treatment time points. NOY1 cells were transfected with siRNAs for 48 h and further treated with 80 µM cisplatin. Cell viability was detected by CellTiter-Glo assay at 0, 24 and 48 h, and the relative viability was normalized to the respective 0 h conditions. N = 3 independent experiments. Two-tailed Student’s t-test, siRNA-NC vs. siRNA-1; p = 1.9 × 10⁻², siRNA-NC vs. siRNA-2: p = 2.0 × 10⁻⁴. E–H NOY1 cells were transfected with siRNAs for 48 h and further treated with 80 μM cisplatin for additional 24–48 h. Cell apoptosis and expression levels of marker proteins in apoptosis (Caspase-3 and cleaved Caspase-3) were determined by flow cytometry (E, F) and western blot (G, H). N = 3 independent experiments. Two-tailed Student’s t-test, at 24 h, siRNA-NC vs. siRNA-1: p = 1.0 × 10⁻⁴, siRNA-NC vs. siRNA-2: p < 10⁻⁴; at 48 h, siRNA-NC vs. siRNA-1: p < 10⁻⁴, siRNA-NC vs. siRNA-2: p < 10⁻⁴. For all in vitro experiments in this study, each one was repeated three times. (A, G and H), β-actin was used as internal control. Uncropped blots of figures are shown in Supplementary Fig. 7. (B, C, D and F), Error bars are presented as means ± s.d. P values were analyzed by two-tailed Student’s t-test. *^/^#p < 0.05, **^/^##p < 0.01, ***^/^###p < 10⁻³, and ****^/^####p < 10⁻⁴.